Terms: = Colorectal cancer AND BRAF, MGC126806, 673, ENSG00000157764, MGC138284, RAFB1, P15056, B-raf 1, BRAF1, B-raf1 AND Treatment
1437 results:
1. The Relationship of Microsatellite Instability with braf and p53 Mutations and Histopathological Parameters in colorectal Adenocarcinoma.
Gündoğar Ö; Bektaş S; Yıldırım E; Gönüllü D
Ann Ital Chir; 2024; 95(2):181-191. PubMed ID: 38684491
[TBL] [Abstract] [Full Text] [Related]
2. Temporal trends and regional variability in braf and KRAS genetic testing in Denmark (2010-2022): Implications for precision medicine.
Frost MG; Jensen KJ; Jimenez-Solem E; Qvortrup C; Kuhlmann TP; Andersen JL; Høgdall E; Petersen TS
Genes Chromosomes Cancer; 2024 Apr; 63(4):e23236. PubMed ID: 38656617
[TBL] [Abstract] [Full Text] [Related]
3. treatment of patients with braf
Germani MM; Vetere G; Santamaria F; Intini R; Ghelardi F; Bensi M; Boccaccino A; Minelli A; Carullo M; Ciracì P; Passardi A; Santucci S; Giampieri R; Persano M; Fenocchio E; Puccini A; Lonardi S; Pietrantonio F; Salvatore L; Cremolini C
ESMO Open; 2024 Apr; 9(4):102996. PubMed ID: 38613911
[TBL] [Abstract] [Full Text] [Related]
4. Structure-Guided Discovery and Preclinical Assessment of Novel (Thiophen-3-yl)aminopyrimidine Derivatives as Potent ERK1/2 Inhibitors.
Shuai W; Xiao H; Yang P; Zhang Y; Bu F; Wu Y; Sun Q; Wang G; Ouyang L
J Med Chem; 2024 Apr; 67(8):6425-6455. PubMed ID: 38613499
[TBL] [Abstract] [Full Text] [Related]
5. Epidemiological and clinicopathological features of KRAS, NRAS, braf mutations and MSI in Chinese patients with stage I-III colorectal cancer.
Wang W; Wang R; Han X; Zhang W; Zhu L; Gu Y
Medicine (Baltimore); 2024 Apr; 103(14):e37693. PubMed ID: 38579072
[TBL] [Abstract] [Full Text] [Related]
6. Current landscape of preoperative neoadjuvant therapies for initial resectable colorectal cancer liver metastasis.
Cheng XF; Zhao F; Chen D; Liu FL
World J Gastroenterol; 2024 Feb; 30(7):663-672. PubMed ID: 38515943
[TBL] [Abstract] [Full Text] [Related]
7. Dynamic ctDNA-based analysis of drug-resistant gene alterations at RAS/braf wild-type metastatic colorectal cancer patients after cetuximab plus chemotherapy as the first-line treatment.
Zhou YW; Zhao X; Ni L; Cao P; Leng WB; Zhu Q; Gou HF; Zhang J; Li XF; Qiu M
Int Immunopharmacol; 2024 Apr; 131():111887. PubMed ID: 38503018
[TBL] [Abstract] [Full Text] [Related]
8. Trastuzumab plus pertuzumab for HER2-amplified advanced colorectal cancer: Results from the drug rediscovery protocol (DRUP).
Spiekman IAC; Zeverijn LJ; Geurts BS; Verkerk K; Haj Mohammad SF; van der Noort V; Roepman P; de Leng WWJ; Jansen AML; Gootjes EC; de Groot DA; Kerver ED; van Voorthuizen T; Roodhart JML; Valkenburg-van Iersel LBJ; Gelderblom H; Voest EE; Verheul HMW
Eur J Cancer; 2024 May; 202():113988. PubMed ID: 38471288
[TBL] [Abstract] [Full Text] [Related]
9. Myotubularin-related-protein-7 inhibits mutant (G12V) K-RAS by direct interaction.
Weidner P; Saar D; Söhn M; Schroeder T; Yu Y; Zöllner FG; Ponelies N; Zhou X; Zwicky A; Rohrbacher FN; Pattabiraman VR; Tanriver M; Bauer A; Ahmed H; Ametamey SM; Riffel P; Seger R; Bode JW; Wade RC; Ebert MPA; Kragelund BB; Burgermeister E
Cancer Lett; 2024 Apr; 588():216783. PubMed ID: 38462034
[TBL] [Abstract] [Full Text] [Related]
10. Evolving survival gains in patients with young-onset colorectal cancer and synchronous resectable liver metastases.
Maki H; Haddad A; Lendoire M; Newhook TE; Peacock O; Bednarski BK; Konishi T; Vauthey JN; You YN
Eur J Surg Oncol; 2024 Apr; 50(4):108057. PubMed ID: 38461567
[TBL] [Abstract] [Full Text] [Related]
11. Fully semantic segmentation for rectal cancer based on post-nCRT MRl modality and deep learning framework.
Xia S; Li Q; Zhu HT; Zhang XY; Shi YJ; Yang D; Wu J; Guan Z; Lu Q; Li XT; Sun YS
BMC Cancer; 2024 Mar; 24(1):315. PubMed ID: 38454349
[TBL] [
